Biotech
Neuralink
Neuralink raises $650M Series D at $8B valuation
$650M
Total Raised
Series D
Latest Round
2016
Founded
400+
Employees
Fremont, CA
1 min read
Quick Facts
Valuation
$8B
Latest Round Size
$650M
Latest Round Date
May 2025
Neuralink: Series D Funding Round
Neuralink has successfully raised $650M in Series D funding, reaching a valuation of $8B.
Company Overview
Brain-computer interface technology
Funding Details
The Series D round was led by Founders Fund, with participation from DFJ Growth.
Company Information
- Headquarters: Fremont, CA
- Founded: 2016
- Employees: 400+
- Category: Biotech
Investment
Neuralink plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Founders Fund: Verified investor in Series D
- DFJ Growth: Verified investor in Series D
Key Investors
Founders Fund
Lead Investor
Verified investor in Series D
DFJ Growth
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M